COMPLETE KIT INCLUDEDbacteriostatic water, syringes, protocol and guide with every order

Certified by ISSCA in Peru and Colombia•ISSCA World Peptide ConferencePERU 2026•Certified by ISSCA in Peru and Colombia•ISSCA World Peptide ConferencePERU 2026•Certified by ISSCA in Peru and Colombia•ISSCA World Peptide ConferencePERU 2026•Certified by ISSCA in Peru and Colombia•ISSCA World Peptide ConferencePERU 2026•
BioPeptideX logoBioPeptideX
Back

Research guide · Recovery & Repair

BPC-157 — research protocol

Pentadecapeptide studied for tissue repair and gut health protocols.

Evidence boundary

This guide summarizes study areas and sources associated with the compound. BioPeptideX does not convert experimental information into a clinical regimen or recommend an individual dose, frequency, route or duration.

Catalog presentations

10mg15mg

Concentration table

Mathematical reference only; this is not a dosing recommendation.

Resulting concentration5.00 mg/mL
On a U-100 syringe · 1 unit contains0.050 mg

Research areas

  • Pentadecapeptide
  • Tissue repair
  • 99% HPLC purity

Most-cited research protocols

Educational information based on research protocols and literature; it does not replace guidance from a healthcare professional.

BPC-157 is a synthetic 15-amino-acid peptide often studied in animal models for tendon, ligament, gut, and vessel injury. Research typically uses subcutaneous injection or oral capsule formats.

DoseFrequencyDurationRoute
Injectable (SubQ) Low~250 mcgOnce dailyN/ASubcutaneous injection
Injectable (SubQ) Standard~250 mcgTwice dailyN/ASubcutaneous injection
Injectable (SubQ) High~500 mcgTwice dailyN/ASubcutaneous injection
Oral/Capsule~250-500 mcgOnce or twice dailyN/AOral

Cycle: Standard: 4-6 weeks; Extended: 6-8 weeks; Long: 8-12 weeks. Off periods of 2-4 weeks are common.

Benefits and research observations: Acute pain and injection-site responses are tracked in days 1-7. Range-of-motion and functional self-reports are tracked in weeks 1-2, while animal models show tendon/ligament endpoints in weeks 4-6.

Handling and storage

Store unreconstituted product according to its label and maintain the cold chain where applicable. After any preparation, follow only validated instructions for the specific product and diluent. Do not use if packaging is damaged or the solution shows particles or unexpected changes.

Warnings

Do not use this page for self-diagnosis or self-medication. Pregnancy, breastfeeding, minors, cancer history, allergies, active disease and concurrent treatments require individual professional evaluation.

Published sources

  1. 1.Sikiric P, et al. Curr Pharm Des, 2010.
  2. 2.Seiwerth S, et al. Front Pharmacol, 2021.